NCT02365597 2026-03-19An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial CancerJanssen Research & Development, LLCPhase 2 Active not recruiting239 enrolled 32 charts 1 FDA
NCT03036098 2026-03-06CheckMate901Bristol-Myers SquibbPhase 3 Active not recruiting1,314 enrolled 23 charts 1 FDA